Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - Science 37 Holdings, Inc. (0001819113) (Filer)
8-K - Lifesci Acquisition II Corp. (0001819113) (Filer)
424B3 - Lifesci Acquisition II Corp. (0001819113) (Filer)
3 - Science 37 Holdings, Inc. (0001819113) (Issuer)
3 - Science 37 Holdings, Inc. (0001819113) (Issuer)
3 - Science 37 Holdings, Inc. (0001819113) (Issuer)
Science 37 to debut on Nasdaq as a publicly traded company under ticker symbol "SNCE"Business combination will provide Science 37 with approximately $235 million in cash proceeds to support continued growthScience 37 to fuel its mission to enable universal access to clinical research which has proven to accelerate patient enrollment, minimize patient burden, and include underserved patient populations Investments targeted to enhance the Science 37 Operating System to decentralize clinical trial execution and enable more agile clinical trials LOS ANGELES and NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Science 37, Inc., the Operating System for today's agile clinical trials, announced today
NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ:LSAQ), a blank check company formed for the purpose of pursuing targets that are focused on healthcare innovation, today announced the confidential submission with the U.S. Securities and Exchange Commission ("SEC") of a draft registration statement on Form S-4 (the "Registration Statement") relating to its previously announced proposed business combination with Science 37, Inc. About LifeSci Acquisition II Corp. LifeSci Acquisition II Corp. (NASDAQ:LSAQ) is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganizat
Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research $80 million via LifeSci Acquisition II Corp., a special purpose acquisition company with no public warrants $200 million via fully committed and upsized PIPE from leading institutional and strategic investors including Redmile Group; funds and accounts managed by BlackRock; Casdin Capital; dRx Capital (Novartis Pharma AG); LifeSci Venture Partners; Lux Capital; Mubadala Capital, the asset manageme
SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)